| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Associations between onset age and disability in multiple sclerosis patients studied using MSSS and a progression model
|
Ramachandran, Sudarshan
|
|
2014
|
3 |
5 |
p. 593-599
7 p.
|
artikel
|
| 2 |
A web-based decision support tool for prognosis simulation in multiple sclerosis
|
Veloso, Mário
|
|
2014
|
3 |
5 |
p. 575-583
9 p.
|
artikel
|
| 3 |
CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination
|
Holley, Janet E.
|
|
2014
|
3 |
5 |
p. 650-658
9 p.
|
artikel
|
| 4 |
Continuous prediction of secondary progression in the individual course of multiple sclerosis
|
Skoog, Bengt
|
|
2014
|
3 |
5 |
p. 584-592
9 p.
|
artikel
|
| 5 |
Corrigendum to “The case for vitamin D supplementation in multiple sclerosis” [Mult. Scler. Relat. Disord. 2 (2013) 281–306]
|
Ganesh, Aravind
|
|
2014
|
3 |
5 |
p. 666-
1 p.
|
artikel
|
| 6 |
EAE is not a useful model for demyelinating disease
|
Behan, Peter O.
|
|
2014
|
3 |
5 |
p. 565-574
10 p.
|
artikel
|
| 7 |
Editors׳ welcome
|
Banwell, Brenda
|
|
2014
|
3 |
5 |
p. 553-554
2 p.
|
artikel
|
| 8 |
Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely
|
Baker, David
|
|
2014
|
3 |
5 |
p. 555-564
10 p.
|
artikel
|
| 9 |
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
|
Hughes, Bruce
|
|
2014
|
3 |
5 |
p. 620-628
9 p.
|
artikel
|
| 10 |
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
|
DiMarco, John P.
|
|
2014
|
3 |
5 |
p. 629-638
10 p.
|
artikel
|
| 11 |
Immune reconstitution inflammatory syndrome and natalizumab–Is it possible before removing the drug?
|
Mulero, P.
|
|
2014
|
3 |
5 |
p. 659-661
3 p.
|
artikel
|
| 12 |
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
|
Fox, Edward
|
|
2014
|
3 |
5 |
p. 607-619
13 p.
|
artikel
|
| 13 |
Physical and social environment and the risk of multiple sclerosis
|
Magyari, Melinda
|
|
2014
|
3 |
5 |
p. 600-606
7 p.
|
artikel
|
| 14 |
P wave duration and dispersion and QT interval in multiple sclerosis
|
Razazian, Nazanin
|
|
2014
|
3 |
5 |
p. 662-665
4 p.
|
artikel
|
| 15 |
Risk stratification and mitigation in multiple sclerosis
|
Ontaneda, Daniel
|
|
2014
|
3 |
5 |
p. 639-649
11 p.
|
artikel
|
Tijdschrift beschrijving